Nabi Seeking StaphVAX Indication For All At-Risk Groups; BLA By End Of 2005
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nabi is initiating immunogenicity trials of its S. aureus vaccine StaphVAX in new patient groups in hopes of securing a broad approval for use in all at-risk adults.